Page 80 - 2019_07 resto del Mondo-web

T. Mährle et al.
AB
C
D
Figure 1. TRB and IGH V- and J-gene usage before and after lenalidomide treatment in patients with del(5q) myelodysplastic syndromes and in healthy controls. For each sample from healthy controls and patients with del(5q) myelodysplastic syndromes before (baseline) and after lenalidomide therapy, the frequency of the V-J gene combi- nations of all IGH and TRB clones was calculated separately as a percentage. The median frequencies, in percentages, are shown for (A,B) IGH and (C,D) TRB V-J-gene combinations for healthy controls and patients, before and after lenalidomide treatment, in (A,C) bone marrow and (B,D) peripheral blood samples as heat maps. Light blue represents lowest frequency and dark blue highest frequency. For both IGH and TRB, J genes are listed along the x axis and functional V genes along the y axis. BM: bone marrow; PB: peripheral blood; MDS; myelodysplastic syndrome; baseline: prior to lenalidomide treatment; post lena: after lenalidomide treatment
1358
haematologica | 2019; 104(7)